A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2028

Conditions

CLL / SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)

Interventions

DRUG

ZE 50-0134

oral capsules QD

Trial Locations (4)

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

RECRUITING

Norton Cancer Institute, St. Matthews Campus, Louisville

RECRUITING

The Ohio State University, Columbus

RECRUITING

University of Cincinnati, Cincinnati